Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.70095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Claire Spahn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Stanford Health Care, Stanford, California, USA. Hauptthemen laut MEDLINE: Pharmacovigilance, Pharmacogenetics, Precision Medicine, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Pharmacovigilance is a critical component of medication safety. Despite rigorous evaluation of new drugs during clinical trials, some adverse effects might only be identified once pharmaceuticals are used by a larger population for a longer duration. Adverse drug reactions cause negative healthcare outcomes and in severe cases, may lead to hospital admissions, delayed hospital discharges, or deaths. Adverse event reports submitted to pharmacovigilance programs by healthcare professionals and consumers are a key source of information regarding previously unrecognized detrimental effects. Pharmacogenetic markers that indicate how particular genes impact an individual’s response to medication can help explain some idiosyncratic adverse reactions. Incorporating pharmacogenomic guidance in prescribing is proven to decrease the incidence of adverse reactions and improve clinical outcomes. However, this information is not yet routinely included in incident reports. In this era of precision medicine, when prescribing can be tailored to the individual, pharmacogenomic test results yield valuable data that can enhance both individual and population health. Furthermore, advanced artificial intelligence (AI) and machine learning (ML) methods facilitate analysis of complex genetic data, revealing insights not previously available. This white paper outlines current pharmacovigilance and pharmacogenomic practices and recommends that pharmacovigilance programs include pharmacogenomics as a crucial data point in their investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy, Stanford Health Care, Stanford, California, USA.
- Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
- Personalized Medicine, Healthcare Quality and Safety Center of Excellence, United States Pharmacopeia, Rockville, Maryland, USA.
- InnoVigilance, Laval, Québec, Canada.
- International Society of Pharmacovigilance, Geneva, Switzerland.
- Department of Translational Medical Sciences, School of Medicine, Texas A&M University, Bryan, Texas, USA.
ORCID-Profile: Claire Spahn, Nanase Toda, Blaine Groat, Omar Aimer, Sara Rogers, Akinyemi Oni-Orisan, Nancy Hakooz
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Spahn, C., Toda, N., Groat, B., Aimer, O., Rogers, S., Oni-Orisan, A., Monte, A., Hakooz, N., & Pharmacogenomics Global Research Network (PGRN) Publications Committee (2025). Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70095
Vancouver
Spahn C, Toda N, Groat B, Aimer O, Rogers S, Oni-Orisan A, et al. Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70095
BibTeX
@article{Spahn2025,
author = {Spahn, Claire and Toda, Nanase and Groat, Blaine and Aimer, Omar and Rogers, Sara and Oni-Orisan, Akinyemi and Monte, Andrew and Hakooz, Nancy and Pharmacogenomics Global Research Network (PGRN) Publications Committee, Pharmacogenomics Global Research Network (PGRN) Publications Committee},
title = {Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.70095}
}
EUVIMED